$EOLS
Evolus Inc Stock $eols

$eols Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000157056220000061 Filed on February 25, 2020

Income Statement

Concept	2019 Q1	2019	2018 Q4
Revenue	$0.00	$34.93M	$0.00
YoY Change
Cost Of Revenue	$0.00	$8.014M
YoY Change
Gross Profit	$0.00	$26.91M
YoY Change
Gross Profit Margin		77.05%
Selling, General & Admin	$17.52M	$113.6M	$12.22M
YoY Change	404.87%	289.74%	640.61%
% of Gross Profit		422.11%
Research & Development	$2.353M	$3.973M	$1.180M
YoY Change	40.23%	-38.75%	-2.48%
% of Gross Profit		14.76%
Depreciation & Amortization	$484.0K	$4.132M	$0.00
YoY Change		45811.11%
% of Gross Profit		15.35%
Operating Expenses	$25.27M	$125.9M	$13.41M
YoY Change	318.01%	172.76%	368.88%
Operating Profit	-$25.27M	-$98.95M
YoY Change	318.01%	114.44%
Interest Expense	-$230.0K	-$6.110M	$90.00K
YoY Change	-314.95%	-808.0%
% of Operating Profit
Other Income/Expense, Net	-$618.0K	-$7.953M
YoY Change	477.57%	821.55%
Pretax Income	-$25.50M	-$105.1M	-$12.42M
YoY Change	314.47%	124.48%	334.27%
Income Tax	-$14.52M	-$15.03M	$20.00K
% Of Pretax Income
Net Earnings	-$10.98M	-$90.03M	-$12.44M
YoY Change	78.11%	92.11%	-379.55%
Net Earnings / Revenue		-257.79%
Basic Earnings Per Share
Diluted Earnings Per Share	-$401.8K	-$3.188M	-$454.7K
COMMON SHARES
Basic Shares Outstanding	27.27M shares		27.27M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q1	2019	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$133.7M	$129.8M	$93.16M
YoY Change	169.56%	39.27%
Cash & Equivalents	$54.40M	$109.9M	$93.16M
Short-Term Investments	$79.30M	$19.90M	$0.00
Other Short-Term Assets	$2.800M	$5.300M	$1.200M
YoY Change	460.0%	341.67%	500.0%
Inventory	$2.578M	$6.400M	$0.00
Prepaid Expenses
Receivables		$10.70M	$0.00
Other Receivables		$0.00
Total Short-Term Assets	$139.1M	$152.2M	$94.34M
YoY Change	177.55%	61.4%	29.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$800.0K	$5.000M	$0.00
YoY Change
Goodwill	$21.21M		$21.21M
YoY Change	0.0%		0.0%
Intangibles	$58.78M		$56.08M
YoY Change	4.83%		0.0%
Long-Term Investments
YoY Change
Other Assets	$1.045M	$2.400M	$221.0K
YoY Change		1100.0%	-89.6%
Total Long-Term Assets	$81.85M	$88.20M	$77.51M
YoY Change	5.9%	13.81%	-2.4%
TOTAL ASSETS
Total Short-Term Assets	$139.1M	$152.2M	$94.34M
Total Long-Term Assets	$81.85M	$88.20M	$77.51M
Total Assets	$220.9M	$240.4M	$171.8M
YoY Change	73.42%	39.93%	12.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.863M	$5.800M	$1.558M
YoY Change	240.59%	262.5%	250.11%
Accrued Expenses	$6.735M	$15.20M	$3.718M
YoY Change	186.35%	310.81%	280.55%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$9.400M	$24.40M	$5.276M
YoY Change	159.02%	360.38%	-97.52%
LONG-TERM LIABILITIES
Long-Term Debt	$72.56M	$91.50M	$0.00
YoY Change	350.66%	441.42%
Other Long-Term Liabilities	$45.90M	$45.10M	$50.20M
YoY Change	13.05%	-10.16%
Total Long-Term Liabilities	$72.56M	$136.6M	$0.00
YoY Change	27.97%	103.58%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.400M	$24.40M	$5.276M
Total Long-Term Liabilities	$72.56M	$136.6M	$0.00
Total Liabilities	$145.6M	$161.0M	$87.46M
YoY Change	93.03%	84.0%	-61.6%
SHAREHOLDERS EQUITY
Retained Earnings	-$134.0M		-$123.0M
YoY Change	62.78%		62.85%
Common Stock	$1.000K		$1.000K
YoY Change	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$75.36M	$79.50M	$84.38M
YoY Change
Total Liabilities & Shareholders Equity	$220.9M	$240.4M	$171.8M
YoY Change	73.42%	39.93%	12.88%

Cashflow Statement

Concept	2019 Q1	2019	2018 Q4
OPERATING ACTIVITIES
Net Income	-$10.98M	-$90.03M	-$12.44M
YoY Change	78.11%	92.11%	-379.55%
Depreciation, Depletion And Amortization	$484.0K	$4.132M	$0.00
YoY Change		45811.11%
Cash From Operating Activities	-$19.20M	-$93.38M	-$12.01M
YoY Change	772.33%	263.36%	1101.0%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$345.0K	$0.00
YoY Change		3733.33%
Acquisitions
YoY Change
Other Investing Activities	-$79.20M	-$18.87M
YoY Change
Cash From Investing Activities	-$80.03M	-$23.43M	$0.00
YoY Change		260277.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$73.32M
YoY Change	-100.0%	8.33%
Debt Paid & Issued, Net	$0.00	$1.044M
YoY Change
Cash From Financing Activities	$60.43M	$133.5M	0.000
YoY Change	16.73%	12.38%	-100.0%
NET CHANGE
Cash From Operating Activities	-$19.20M	-$93.38M	-12.01M
Cash From Investing Activities	-$80.03M	-$23.43M	0.000
Cash From Financing Activities	$60.43M	$133.5M	0.000
Net Change In Cash	-$38.80M	$16.73M	-12.01M
YoY Change	-178.26%	-82.04%
FREE CASH FLOW
Cash From Operating Activities	-$19.20M	-$93.38M	-$12.01M
Capital Expenditures	$0.00	$345.0K	$0.00
Free Cash Flow	-$19.20M	-$93.73M	-$12.01M
YoY Change		264.57%	1101.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001570562
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33728035	shares
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2019	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4132000	USD
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019Q2	dei	Entity Public Float EntityPublicFloat	238700000	USD
CY2019	eols	Allocated Share Based Compensation Expense Capitalized AllocatedShareBasedCompensationExpenseCapitalized	106000	USD
CY2018	eols	Capital Contribution Convertible Note Write Off CapitalContributionConvertibleNoteWriteOff	66998000	USD
CY2019	eols	Capital Contribution Convertible Note Write Off CapitalContributionConvertibleNoteWriteOff	0	USD
CY2018Q1	eols	Capital Contribution Forgivenessof Related Party Borrowings CapitalContributionForgivenessofRelatedPartyBorrowings	13188000	USD
CY2018	eols	Capital Contribution Forgivenessof Related Party Borrowings CapitalContributionForgivenessofRelatedPartyBorrowings	13188000	USD
CY2019	dei	Entity Registrant Name EntityRegistrantName	EVOLUS, INC.
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019	dei	Entity Small Business EntitySmallBusiness	true
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018	eols	Accounts Payable Paidby Parent AccountsPayablePaidbyParent	163000	USD
CY2019	eols	Accounts Payable Paidby Parent AccountsPayablePaidbyParent	0	USD
CY2018	eols	Allocated Share Based Compensation Expense Capitalized AllocatedShareBasedCompensationExpenseCapitalized	0	USD
CY2019	eols	Capital Contribution Forgivenessof Related Party Borrowings CapitalContributionForgivenessofRelatedPartyBorrowings	0	USD
CY2018	eols	Capital Contribution From Parent Forgiveness Of Related Party Borrowings CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings	13188000	USD
CY2018Q4	eols	Common Stock Additional Capital Shares Reservedfor Future Issuance CommonStockAdditionalCapitalSharesReservedforFutureIssuance	1091000	shares
CY2019Q4	eols	Common Stock Additional Capital Shares Reservedfor Future Issuance CommonStockAdditionalCapitalSharesReservedforFutureIssuance	1337821	shares
CY2018	eols	Contingent Promissory Note ContingentPromissoryNote	16042000	USD
CY2019	eols	Contingent Promissory Note ContingentPromissoryNote	0	USD
CY2018	eols	Contingent Royalty Obligation ContingentRoyaltyObligation	39700000	USD
CY2019	eols	Contingent Royalty Obligation ContingentRoyaltyObligation	0	USD
CY2018Q4	eols	Contingent Royalty Obligation Payableto Related Party Current ContingentRoyaltyObligationPayabletoRelatedPartyCurrent	0	USD
CY2019Q4	eols	Contingent Royalty Obligation Payableto Related Party Current ContingentRoyaltyObligationPayabletoRelatedPartyCurrent	3483000	USD
CY2018	eols	Deemed Contribution From Parent Increase Of Related Party Receivable DeemedContributionFromParentIncreaseOfRelatedPartyReceivable	1051000	USD
CY2019Q4	eols	Deferred Tax Assets.Operating Lease Liabilities DeferredTaxAssets.OperatingLeaseLiabilities	1274000	USD
CY2018Q4	eols	Deferred Tax Assets Promissory Note Debt Discount DeferredTaxAssetsPromissoryNoteDebtDiscount	101000	USD
CY2019Q4	eols	Deferred Tax Assets Promissory Note Debt Discount DeferredTaxAssetsPromissoryNoteDebtDiscount	199000	USD
CY2018	eols	Effective Income Tax Rate Reconciliation Net Operating Loss Writeoff Amount EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount	0	USD
CY2019	eols	Effective Income Tax Rate Reconciliation Net Operating Loss Writeoff Amount EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount	5174000	USD
CY2018	eols	Effective Income Tax Rate Reconciliation Promissory Note Debt Discount EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount	105000	USD
CY2019	eols	Effective Income Tax Rate Reconciliation Promissory Note Debt Discount EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount	128000	USD
CY2018	eols	Effective Income Tax Rate Reconciliation Revaluation Of Contingent Royalty Obligation EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation	2938000	USD
CY2019	eols	Effective Income Tax Rate Reconciliation Revaluation Of Contingent Royalty Obligation EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation	1040000	USD
CY2019	eols	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-654000	USD
CY2019Q4	eols	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	84699000	USD
CY2019	eols	Lessee Operating Lease Period Of Written Notice Prior To Lease Terminate Date LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate	P12M
CY2019	eols	Lessee Operating Lease Termination Fee Period Of Rent Equivalent LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent	P6M
CY2019	eols	Lessee Operating Lease Termination Period LesseeOperatingLeaseTerminationPeriod	P36M
CY2018Q4	eols	Milestone Payment Current MilestonePaymentCurrent	0	USD
CY2019Q4	eols	Milestone Payment Current MilestonePaymentCurrent	1709000	USD
CY2018	eols	Milestone Payments For Intangible Assets MilestonePaymentsForIntangibleAssets	0	USD
CY2019	eols	Milestone Payments For Intangible Assets MilestonePaymentsForIntangibleAssets	3000000	USD
CY2018	eols	Non Cash Accruedand Unpaid Offering Costs NonCashAccruedandUnpaidOfferingCosts	0	USD
CY2019	eols	Non Cash Accruedand Unpaid Offering Costs NonCashAccruedandUnpaidOfferingCosts	90000	USD
CY2018	eols	Non Cash Deferred Offering Costs NonCashDeferredOfferingCosts	2885000	USD
CY2019	eols	Non Cash Deferred Offering Costs NonCashDeferredOfferingCosts	0	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6000	USD
CY2018	eols	Non Cash Finance And Insurance Payment NonCashFinanceAndInsurancePayment	0	USD
CY2019	eols	Non Cash Finance And Insurance Payment NonCashFinanceAndInsurancePayment	1561000	USD
CY2018	eols	Non Cash Landlord Paid Tenant Improvement NonCashLandlordPaidTenantImprovement	0	USD
CY2019	eols	Non Cash Landlord Paid Tenant Improvement NonCashLandlordPaidTenantImprovement	781000	USD
CY2018	eols	Non Cash Note Obligation NonCashNoteObligation	140688000	USD
CY2019	eols	Non Cash Note Obligation NonCashNoteObligation	0	USD
CY2018	eols	Non Cash Related Party Borrowings NonCashRelatedPartyBorrowings	68767000	USD
CY2019	eols	Non Cash Related Party Borrowings NonCashRelatedPartyBorrowings	0	USD
CY2018	eols	Non Cash Related Party Receivable NonCashRelatedPartyReceivable	73690000	USD
CY2019	eols	Non Cash Related Party Receivable NonCashRelatedPartyReceivable	0	USD
CY2019	eols	Operating Lease Percentage Of Annual Rent Escalation OperatingLeasePercentageOfAnnualRentEscalation	0.03
CY2019	eols	Operating Lease Rightof Use Asset Amortization OperatingLeaseRightofUseAssetAmortization	873000	USD
CY2018	eols	Payments Of Contingent Royalty Obligation PaymentsOfContingentRoyaltyObligation	0	USD
CY2019	eols	Payments Of Contingent Royalty Obligation PaymentsOfContingentRoyaltyObligation	9677000	USD
CY2018	eols	Proceeds From Payments For Issuance Of Common Stock In Connection With Equity Incentive Plan ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan	-239000	USD
CY2019	eols	Proceeds From Payments For Issuance Of Common Stock In Connection With Equity Incentive Plan ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan	2455000	USD
CY2018	eols	Provisions For Rebate And Coupon Programs ProvisionsForRebateAndCouponPrograms	0	USD
CY2019	eols	Provisions For Rebate And Coupon Programs ProvisionsForRebateAndCouponPrograms	12325000	USD
CY2019	eols	Rebates And Coupons Credits And Payments RebatesAndCouponsCreditsAndPayments	10616000	USD
CY2018	eols	Revaluationof Contingent Royalty Obligation Payable RevaluationofContingentRoyaltyObligationPayable	10500000	USD
CY2019	eols	Revaluationof Contingent Royalty Obligation Payable RevaluationofContingentRoyaltyObligationPayable	4160000	USD
CY2018	eols	Stock Issued During Period Value Issuance Of Common Stock In Connection With Incentive Equity Plan StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan	-239000	USD
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3718000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	13960000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1558000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5796000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	0	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10661000	USD
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1038000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3718000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13960000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	931000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5794000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	207408000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	292509000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	66998000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6971000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9624000	USD
CY2018	us-gaap	Advertising Expense AdvertisingExpense	0	USD
CY2019	us-gaap	Advertising Expense AdvertisingExpense	1407000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6971000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9518000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	387000	USD
CY2019	us-gaap	Allowance For Loan And Lease Losses Write Offs AllowanceForLoanAndLeaseLossesWriteOffs	0	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	863000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2156000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3853000	USD
CY2018Q4	us-gaap	Assets Assets	171844000	USD
CY2019Q4	us-gaap	Assets Assets	240442000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	94339000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	152197000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	19911000	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	10500000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	4160000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	87000	USD
CY2018	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	0	USD
CY2019	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	4415000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	93162000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	109892000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	93162000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109892000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	93162000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	16730000	USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2249380	shares
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27274991	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33562665	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27274991	shares
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33562665	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8014000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46867000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-90028000	USD
CY2018Q4	us-gaap	Contractual Obligation ContractualObligation	50200000	USD
CY2019Q4	us-gaap	Contractual Obligation ContractualObligation	41200000	USD
CY2018Q1	us-gaap	Contractual Obligation ContractualObligation	39700000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	28000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	28000	USD
CY2019Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	75000000	USD
CY2019Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1492000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	44000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-10299000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	65000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-15055000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	15055000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	14131000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	15055000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	25000	USD
CY2019Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2019Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	21000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-4756000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	14131000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27929000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	42756000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	11000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	12000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	608000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	1962000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1455000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2430000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	2176000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	2470000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	32280000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36972000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	15055000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	15055000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	12970000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1017000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	144000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	479000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2955000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9000	USD
CY2018	us-gaap	Dividends Dividends	2000000	USD
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.92
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.19
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2577000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5229000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3853000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	41621000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	5423000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2955000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2955000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3729000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	63491000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	59638000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018	us-gaap	Gross Profit GrossProfit	0	USD
CY2019	us-gaap	Gross Profit GrossProfit	26911000	USD
CY2017	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2018	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2019	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-46802000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-105061000	USD
CY2018Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	USD
CY2019Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	65000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15027000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	9801000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4691000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-1371000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-9828000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-22063000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	17000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	1002000	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	474000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	521000	USD
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3148000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3905000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Contingencies Other IncomeTaxReconciliationTaxContingenciesOther	0	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Contingencies Other IncomeTaxReconciliationTaxContingenciesOther	50000	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	294000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	294000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1275000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	183000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11048000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	2733000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2742000	USD
CY2018	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-13000	USD
CY2019	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	0	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4482000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	211000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	190000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	992000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1874000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	56076000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	59638000	USD
CY2018Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	77284000	USD
CY2019Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	80846000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	5166000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	0	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6407000	USD
CY2018	us-gaap	Investment Income Net InvestmentIncomeNet	203000	USD
CY2019	us-gaap	Investment Income Net InvestmentIncomeNet	1839000	USD
CY2018	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	334000	USD
CY2019	us-gaap	Lease Cost LeaseCost	1275000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6459000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	114000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1201000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1369000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1312000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1258000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1205000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1366000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P60M
CY2018Q4	us-gaap	Liabilities Liabilities	87460000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	160985000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	171844000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	240442000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5276000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24439000	USD
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	73508000	USD
CY2019Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	9783000	USD
CY2019Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	39130000	USD
CY2019Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	26087000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	73508000	USD
CY2018Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	16904000	USD
CY2019Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	17945000	USD
CY2018Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	16042000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-93383000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-93400000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-46867000	USD
CY2018Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
CY2019Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	118838000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	133547000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-23434000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25667000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-25700000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-90034000	USD
CY2019	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	unit
CY2018	us-gaap	Operating Expenses OperatingExpenses	46142000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	125858000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-46142000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-98947000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	1080000	USD
CY2019	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	80000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5093000	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1200000	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	916000	USD
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3893000	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	138000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	923000	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4068000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1029000	USD
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.094
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1029000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	890000	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	0	USD
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	139000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	210000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1228000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	221000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2429000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	6000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-863000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7953000	USD
CY2019	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale	0	USD
CY2018	us-gaap	Payments For Software PaymentsForSoftware	0	USD
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	203000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	113867000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	345000	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2019	us-gaap	Payments For Software PaymentsForSoftware	4222000	USD
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	2205000	USD
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1060000	USD
CY2018	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1177000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5326000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	56330000	USD
CY2018	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	56330000	USD
CY2019	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2018Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	67680000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	67680000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	73315000	USD
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	73906000	USD
CY2018	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	USD
CY2019	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	95000000	USD
CY2018	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1127000	USD
CY2019	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	902000	USD
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	387000	USD
CY2019Q4	us-gaap	Purchase Obligation PurchaseObligation	4602000	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1044000	USD
CY2018	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	5000000	USD
CY2019	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6487000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3973000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-123025000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-213059000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34925000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5566000	USD
CY2018Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	12.00
CY2018Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	20.00
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	29146000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	113593000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	6971000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	9518000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	4361291	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	800595	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3977401	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.99
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	14.07
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	12.50
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2311000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	328117	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1321451	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7119000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7198000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3257801	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	7198000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3977401	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	14.07
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.04
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	9.98
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	15.15
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	18.63
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1880000	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y3M11D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y3M4D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M4D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y6M4D
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	85000	USD
CY2018Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3600000	shares
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	273734	shares
CY2018	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	84384000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	79457000	USD
CY2018Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	1.6527
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2109000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2435000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2761000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	326000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	326000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-15055000	USD
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	110000	USD
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24402368	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	28237816	shares
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Risks and Uncertainties</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2013, Evolus and Daewoong Pharmaceuticals Co. Ltd. (“Daewoong”) entered into the Daewoong Agreement, pursuant to which, the Company has the exclusive distribution license to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> from Daewoong for aesthetic indications in the United States, European Union, Great Britain, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company’s commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Daewoong Agreement, and Daewoong’s rights relating to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, are subject to litigation. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 7</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">Commitments and Contingencies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for additional information regarding such litigation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company commercially launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the United States in May 2019 and in Canada through its distribution partner in October 2019 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company’s business and its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and any future product candidates, ability to obtain and maintain regulatory approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and any future product candidates in the jurisdictions where approval is sought, the need for additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all of the Company’s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company’s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company’s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers’ ability to pay.</font></div></div>
CY2019	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Reclassification </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss.</font></div></div>
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Management is required to make certain estimates and assumptions in order to prepare financial statements in conformity with GAAP. Such estimates and assumptions affect the reported financial statements. The Company’s most significant estimates relate to net revenues, allowance for doubtful accounts, fair value measurements, goodwill and long-lived asset valuations and impairment assessments, inventory valuations, income tax valuations, stock-based compensation and royalty obligations, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company’s actual results could differ materially from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001570562-20-000061-index-headers.html	Edgar Link	pending
0001570562-20-000061-index.html	Edgar Link	pending
0001570562-20-000061.txt	Edgar Link	pending
0001570562-20-000061-xbrl.zip	Edgar Link	pending
a900kda.jpg	Edgar Link	pending
adverseeventtable1.jpg	Edgar Link	pending
eols-20191231.xml	Edgar Link	completed
eols-20191231.xsd	Edgar Link	pending
eols-20191231_cal.xml	Edgar Link	unprocessable
eols-20191231_def.xml	Edgar Link	unprocessable
eols-20191231_lab.xml	Edgar Link	unprocessable
eols-20191231_pre.xml	Edgar Link	unprocessable
evolus12311910-k.htm	Edgar Link	pending
exhibit101112311910k.htm	Edgar Link	pending
exhibit23112311910-k.htm	Edgar Link	pending
exhibit31112311910k.htm	Edgar Link	pending
exhibit31212311910k.htm	Edgar Link	pending
exhibit32112311910k.htm	Edgar Link	pending
exhibit4312311910k.htm	Edgar Link	pending
favors.jpg	Edgar Link	pending
favors1.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
secondary.jpg	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EOLS
Evolus Inc Stock $eols

2019 Q1 Form 10-K Financial Statement

#000157056220000061 Filed on February 25, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EOLS Evolus Inc Stock $eols

2019 Q1 Form 10-K Financial Statement

#000157056220000061 Filed on February 25, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EOLS
Evolus Inc Stock $eols